|
|
|
| Effect of Tongxieyao Prescription combined with moxa stick moxibustion on diarrhea type-irritable bowel syndrome and its influence on levels of immunoglobulin and serum inflammatory factors |
| ZHANG Jiao1 CHEN Ting2 LIU Jing3 SHI Bin4 XING Kai5 XU Junlin1 WANG Liying1 TAO Yuan1▲ |
1.Department of Spleen and Stomach Diseases, Beijing Changping District Hospital of Traditional Chinese Medicine, Beijing 102200, China;
2.Department of Spleen and Stomach Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China;
3.Department of Spleen and Stomach Diseases, Yanqing Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing 102100, China;
4.Department of Nephrology, Beijing Changping District Hospital of Integrated Traditional Chinese and Western Medicine, Beijing 100096, China;
5.Department of Ophthalmology, Beijing Changping District Hospital of Traditional Chinese Medicine, Beijing 102200, China |
|
|
|
|
Abstract Objective To explore the effect of Tongxieyao Prescription combined with moxa stick moxibustion on diarrhea type-irritable bowel syndrome (IBS-D) and its influence on levels of immunoglobulin and serum inflammatory factors. Methods A total of 94 patients with IBS-D of liver depression and spleen deficiency type admitted to Department of Spleen and Stomach Diseases, Beijing Changping District Hospital of Traditional Chinese Medicine from July 2019 to October 2022 were selected and they were divided into observation group and control group according to random number table method, with 47 cases in each group. The control group was given Piverium Bromide Tablets, and the observation group was given Tongxieyao Prescription combined with moxa stick moxibustion. Both groups were treated for 14 days. Clinical efficacy, traditional Chinese medicine symptom score, irritable bowel syndrome-symptom severity scale (IBS-SSS) score, irritable bowel syndrome-quality of life (IBS-QOL) score, immunoglobulin level, inflammatory factor level of the two groups were compared, and the occurrence of adverse reactions between the two groups were recorded. Results The clinical effect of the observation group was better than that of the control group (P＜0.05). After treatment, the scores of symptoms of emotional changes cause or aggravate diarrhea, abdominal pain, pain reduction after diarrhea, hypochondriacal swelling pain, dilatation, and often sighing in two groups were lower than before treatment, and those in the observation group was lower than those in the control group (P＜0.05). After treatment, IBS-SSS scores in both groups were lower than before treatment, and that in the observation group was lower than that in the control group (P＜0.05). After treatment, IBS-QOL scores in both groups were higher than before treatment, and that in the observation group was higher than that in the control group (P＜0.05). After treatment, the levels of serum immunoglobulin(Ig)A, IgG and IgM in the two groups were lower than before treatment, and the IgA and IgG in the observation group were lower than those in the control group (P＜0.05). After treatment, the serum levels of interleukin(IL)-6 and tumor necrosis factor-α in both groups were lower than before treatment, and those in the observation group was lower than those in the control group (P＜0.05). After treatment, the serum IL-10 level in both groups was higher than that before treatment, and that in the observation group was higher than that in the control group (P＜0.05). No obvious adverse reactions were observed during treatment. Conclusion Tongxieyao Prescription combined with moxa stick moxibustion can improve the clinical efficacy of IBS-D patients, regulate immunity, control inflammation in vivo, reduce pain and improve symptoms, and is worthy of clinical application.
|
|
|
|
|
|
[1] 魏薇，费贵军.焦虑抑郁状态在肠易激综合征发病机制中的作用[J].中国实用内科杂志，2018，38（1）：77-80.
[2] 尹德菲，魏秀楠，刘佳卉，等.理肠饮治疗腹泻型肠易激综合征肝郁脾虚证的临床疗效及机制研究[J].南京中医药大学学报，2022，38（8）：687-695.
[3] 张声生，魏玮，杨俭勤.肠易激综合征中医诊疗专家共识意见（2017）[J].中医杂志，2017，58（18）：1614-1620.
[4] 中国中西医结合学会消化系统疾病专业委员会.肠易激综合征中西医结合诊疗共识意见（2017年）[J].中国中西医结合消化杂志，2018，26（3）：227-232.
[5] 中华人民共和国卫生部.中药新药临床研究指导原则试行[M]北京：中国医药科技出版社，2002：361-390.
[6] 霍永利，毛竞宇，侯姿蕾，等.温经通络中药热膏摩联合痛泻药方治疗肝郁脾虚证腹泻型肠易激综合征疗效观察[J].中华中医药杂志，2021，36（9）：5689-5692.
[7] 鲁慧，王东旭.香砂六君子汤治疗脾虚湿盛型腹泻型肠易激综合征的中医证候疗效及对血清5-羟色胺、脑源性神经营养因子、神经肽Y的影响[J].河北中医，2021， 43（2）：256-260，269.
[8] 许晓娟，刘亮，姚树坤，等.腹泻型肠易激综合征患者内脏敏感性、肠屏障功能及自主神经功能的评价[J].中南大学学报（医学版），2017，42（5）：522-528.
[9] 王栩芮，傅文斌，孙弋淇，等.痛泄要方缓解肝郁脾虚证腹泻型肠易激综合征患者内脏高敏的临床疗效[J].中国实验方剂学杂志，2022，28（9）：97-102.
[10] 周子娴，马惠芳，杨易陈，等.电针对腹泻型肠易激综合征大鼠结肠动力学及相关蛋白表达的影响[J].针刺研究，2022，47（7）：611-616.
[11] 张艳霞，赵蓉，吕双然，等.七味白术散加味联合脐灸对腹泻型肠易激综合征脾胃虚弱证患者肠道菌群及炎症指标的影响[J].河北中医，2021，43（12）：2046-2051.
[12] 苏健彬，张伦.自拟培土顺木汤治疗肝郁脾虚型腹泻型肠易激综合征临床观察[J].广州中医药大学学报，2022，39（12）：2776-2781.
[13] 刘畅，刘晓燕，张燕，等.痛泻要方加减治疗腹泻型肠道易激综合征临床研究[J].四川中医，2022，40（1）：110- 113.
[14] 张北华，王微，王凤云，等.痛泻要方干预腹泻型肠易激综合征肝郁脾虚证模型大鼠的效应评价[J].中华中医药杂志，2018，33（10）：4341-4346.
[15] 卓冰帆，宁晓燕，张彦卿.痛泻要方合四君子汤对腹泻型肠易激综合征患者免疫功能的影响[J].广东医学，2017，38（23）：3669-3671，3675.
[16] 黄泓轲，罗健玮，李晓婷，等.广藿香油对感染后肠易激综合征大鼠肠黏膜屏障的影响[J].中华医院感染学杂志，2018，28（7）：971-974，990.
[17] 史玉明，居峰.匹维溴铵片联合马来酸曲美布汀分散片治疗肠易激综合征患者的临床研究[J].中国临床药理学杂志，2022，38（23）：2799-2802.
[18] 杨芳，严晶，刘丽娜，等.加味交泰丸联合地衣芽孢杆菌活菌治疗腹泻型肠易激综合征临床疗效及对血清IL-6、IL-8、TNF-α水平影响[J].中华中医药学刊，2021， 39（10）：155-159.
[19] 相雪莲，许丹宁，曹楠，等.白术多糖对环磷酰胺诱导的免疫抑制小鼠白细胞数量及功能的修复作用[J].中国兽医杂志，2020，56（7）：36-41.
[20] 杨艳丽，杜杉杉.白芍总苷对实验性变态反应性脑脊髓炎小鼠免疫功能的影响[J].中国临床药理学杂志，2020， 36（24）：4025-4027，4034.
[21] 宋洁，郭瑞芳，聂虹，等.木香烃内酯对溃疡性结肠炎小鼠肠道免疫炎症的影响及其机制[J].广西医科大学学报，2021，38（12）：2300-2305.
[22] 刘淇，高铭，吕红君，等.防风乙醇提取物对LPS所致小鼠炎症模型的抗炎作用及机制研究[J].中国中药杂志，2021，46（18）：4800-4807.
[23] 柴常伟，张海婧，吴练秋.基于网络药理学的砂仁抗溃疡性结肠炎机制研究[J].药学学报，2022，57（11）：3345-3355.
[24] 郑薇薇，赵耀，刘兴山.火龙灸联合久泻方治疗脾肾阳虚型腹泻型肠易激综合征疗效及对肠黏膜屏障、炎症因子、脑肠轴的影响[J].现代中西医结合杂志，2022，31（16）：2191-2196，2204.
[25] 林雨清，谢雪华，章浩军，等.八段锦运动联合艾灸疗法对腹泻型肠易激综合征患者生活质量的研究[J].中国医药科学，2022，12（9）：131-134.
[26] 姜悦航，张越，王妍妍，等.茯苓多糖提取物调控CYP2E1及NF-κB炎症通路改善小鼠酒精性肝病[J].中国中药杂志，2022，47（1）：134-140. |
|
|
|
